Lorexys: Phase IIa started

S1 Biopharma began the open-label, 3-way crossover, U.S. Phase IIa PURPLE trial to compare daily Lorexys vs. daily bupropion in 30 premenopausal women with HSDD. Patients will sequentially receive bup...